Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BOL-303224-A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BOL-303224-A | EXPERIMENTAL | Systemic exposure of BOL-303224-A following single and multiple topical doses |
| Name | Type | Description |
|---|---|---|
| BOL-303224-A | DRUG | 1 drop in each eye, TID for 5 days at approximately 6 h intervals, with a final, single dose on the morning of Visit 7 (Day 6). |
Inclusion Criteria: * must be at least 18 years of age, any race * must have a clinical diagnosis of acute bacterial conjunctivitis and exhibit purulent conjunctival discharge and redness in both eyes * women of childbearing potential must utilize reliable contraceptive methods and have a negative ...
BOL-303224-A is an investigational small molecule being developed for bacterial conjunctivitis, an eye infection. It is in Phase 1 clinical development and is not yet approved by the FDA. The drug is being studied for its systemic pharmacokinetics in patients with this condition.
BOL-303224-A is being developed by Bausch + Lomb Corporation, a company traded on the New York Stock Exchange under the ticker BLCO. The company is conducting clinical research on this investigational drug for bacterial conjunctivitis.
BOL-303224-A is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not received FDA approval and is still in the early stages of clinical testing for bacterial conjunctivitis.
BOL-303224-A has one completed Phase 1 clinical trial registered as NCT00407589, titled "Systemic Pharmacokinetics of BOL-303224-A." The trial enrolled 24 participants in the United States and studied the drug's systemic exposure in patients with bacterial conjunctivitis.
No, BOL-303224-A is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for bacterial conjunctivitis. A Phase 1 trial has been completed, but the drug has not yet progressed to later-stage trials or received regulatory approval.